Lecia V. Sequist
Defined EGFR resistance mechanisms in lung cancer and now leads early-detection research including the Sybil AI lung-risk model.
Thoracic oncologist who led the 2011 analysis of resistance to EGFR inhibitors and the early osimertinib development; now directs MGH's early cancer detection centre and co-developed Sybil.
| Title | Journal | Year |
|---|---|---|
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Science Translational Medicine | 2011 |
| Sybil: a validated deep learning model to predict future lung cancer risk from a single low-dose chest computed tomography | Journal of Clinical Oncology | 2023 |
Pages like this
not linked directly; found by shared links- PersonDaniel A. Haber
Shares Massachusetts General Hospital Cancer Center, EGFR, Non-small-cell lung cancer.
- PersonWeimin Li
Shares Low-dose CT lung screening, AI in radiology, Non-small-cell lung cancer.
- TechnologySybil (MIT/MGH lung cancer risk from CT)
Shares Massachusetts General Hospital Cancer Center, AI in radiology, Non-small-cell lung cancer.
- TechnologyMirai (MIT breast cancer risk from mammograms)
Shares Massachusetts General Hospital Cancer Center, AI in radiology.
- TrialLAURA
Shares EGFR, Non-small-cell lung cancer.
- CollectionLUNGevity Foundation (and GO2 for Lung Cancer)
Shares Low-dose CT lung screening, EGFR, Non-small-cell lung cancer.
- InstitutionMUSC Hollings Cancer Center
Shares Low-dose CT lung screening, Non-small-cell lung cancer.
- ProductDacomitinib
Shares EGFR, Non-small-cell lung cancer.